Oncology Central

NICE approves dabrafenib–trametinib for BRAF+ melanoma

NICE have approved dabrafenib plus trametinib as an option for the adjuvant treatment of resected stage III BRAF V600 mutation-positive melanoma in adults.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.